Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore

Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore

10.1080/14737167.2023.2295474

Saved in:

Bibliographic Details
Main Authors:	Elaine Hsuen Lim, Andrew Lim, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Matt Griffiths, Emma New, Soo-chin Lee
Other Authors:	MEDICINE
Format:	Article
Published:	Taylor & Francis 2024
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/247511
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: An in silico based mechanism
by: Fuentes, G., et al.
Published: (2014)

Not all therapeutic antibody isotypes are equal: The case of IgM: Versus IgG in Pertuzumab and Trastuzumab
by: Samsudin, F., et al.
Published: (2021)

Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer
by: Jitawatanarat,P., et al.
Published: (2015)

Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer
by: Potjana Jitawatanarat, et al.
Published: (2018)

Trastuzumab decorated nanoparticles for targeted chemotherapy of breast cancer
by: Sun, B., et al.
Published: (2014)

Trastuzumab decorated nanoparticles for targeted chemotherapy of breast cancer
by: Sun, B., et al.
Published: (2014)

Increasing Neoadjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients
by: Muhtarum Yusuf, -, et al.
Published: (2020)

Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
by: Lim L.Y., et al.
Published: (2018)

Trastuzumab-decorated nanoparticles of biodegradable polymers for targeted small molecule chemotherapy
by: SUN BINGFENG
Published: (2010)

Statistical considerations in biosimilar assessment using biosimilarity index
by: Zhang, A, et al.
Published: (2020)

Side Effects of Drugs in Patients with Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy
by: Nadhila Pratiwi, -, et al.
Published: (2020)

Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy
by: Suebwong Chuthapisith, et al.
Published: (2018)

Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer
by: Tan, Hong Qi, et al.
Published: (2022)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
by: Jiraporn Setakornnukul, et al.
Published: (2019)

DE NOVO DESIGN OF ANTIMICROBIAL PEPTIDES FOR APPLICATION AS ANTI-INFECTIVE AGENTS
by: JASMEET SINGH KHARA
Published: (2017)

On the regulatory approval pathway of biosimilar products
by: Wang, J, et al.
Published: (2020)

Pathological and Oncologic Outcomes of Consolidation Chemotherapy in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiation
by: Tawantanakorn T.
Published: (2023)

Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study
by: Saxena, N., et al.
Published: (2014)

Neutrophil Lymphocyte Ratio as Predictive Factor Radiological Response of Neoadjuvant Chemotherapy In Locally Advanced Rectal Cancer
by: Wardhana, Adhitya Angga, et al.
Published: (2021)

Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (review)
by: Suebwong Chuthapisith, et al.
Published: (2018)

Efficacy and safety of rituximab biosimilar in refractory lupus
by: Nantakarn Pongtarakulpanit, et al.
Published: (2020)

The use of various parameters of 99m Tc-sestamibi scintimammography to predict response of breast cancer to neoadjuvant chemotherapy
by: Tanyaluk Sriwongsa, et al.
Published: (2006)

Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients
by: Sutima Luangdilok, et al.
Published: (2018)

Platelet To Lymphocyte Ratio Relationship With Neoadjuvant Chemotherapy Of CAF Regiment Response In Locally Advanced Breast Cancer Patients
by: Ali Sibra Mulluzi, et al.
Published: (2021)

Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer
by: Sun, B., et al.
Published: (2014)

Neoadjuvant carboplatin and 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: Primary report
by: P. Tepmongkol, et al.
Published: (2018)

Tumour infiltrating lymphocyts (TILs) as an excellent predictive factor for neoadjuvant chemotherapy response on locally advanced rectal cancer patient
by: Florencia Adys, -, et al.

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
by: Praditpornsilpa K., et al.
Published: (2017)

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
by: Kearkiat Praditpornsilpa, et al.
Published: (2018)

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies
by: Kearkiat Praditpornsilpa, et al.
Published: (2018)

Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer
by: Zhang, Jun, et al.
Published: (2022)

Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
by: Wang X.J., et al.
Published: (2018)

Confidence region approach for assessing bioequivalence and biosimilarity accounting for heterogeneity of variability
by: Li, J, et al.
Published: (2020)

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
by: Glynne-Jones, R, et al.
Published: (2020)

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: Interim results from 2 prospective phase 2 clinical trials
by: Kong, L., et al.
Published: (2016)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
by: Sun, B., et al.
Published: (2014)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
by: Sun, B., et al.
Published: (2014)

Comparative study of bulky stage IB and IIA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: Long-term follow-up
by: Manusirivithaya S., et al.
Published: (2014)

The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: Napat Saigosoom, et al.
Published: (2020)

The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer - A systematic review and meta-analysis
by: Tan, V.K.M., et al.
Published: (2016)